Immunoradiometric measurement of pS2 in breast cancer - Correlation with steroid receptors and plasminogen activators

Acta Oncologica

Volumn 38, Issue 6, 1999, Pages 805-814

  Luqmani, Yunus ^a   Temmim, Labiba ^b   Memon, Anjum ^b   Parkar, Abdulhamid ^b   Ali, Majda ^b   Motawy, Mohammed ^b   Baker, Hisham ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR; PROTEIN PS2; STEROID RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PROTEINS; RECEPTORS, STEROID; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; TUMOR SUPPRESSOR PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032826365     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432978     Document Type: Article

References (53)

1. McGuire WL, Carbone PP, Vollmer RP, editors. Estrogen receptors in human breast cancer. New York: Raven Press, 1975.
2. Lippman ME, Allegra JC. Quantitative estrogen receptor analysis: the response to endocrine and cytotoxic therapy in human breast cancer and the disease free interval. Cancer 1980; 46: 2829-34.
3. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189: 726-7.
4. Desombre ER. Thorpe SM, Rose C, et al. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res 1986; 46 (Suppl): 4256s-64s.
5. Williams MR, Todd JH, Ellis O, et al. Oestrogen receptors in primary and advanced breast cancer: an eight-year review of 704 cases. Br J Cancer 1987: 55: 67-73.
6. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 1993; 309: 1343-7.
7. Alexieva-Figusch J, Van Putten WLJ, Blankenstein MA, Blonk Van Der Wijst J, Klijn JG. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 1988; 61: 758-68.
8. Collett K, Skjaerven R, Thorsen T. Hartveit F, Maehle BO. The prognostic role of progesterone receptor status and age in relation to axillary node status in breast cancer patients. Eur J Clin Oncol 1989; 25: 959-64.
9. Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer: a sequential multi-variate analysis of 1 262 patients. Eur J Clin Oncol 1989; 25: 1233-40.
10. Hawkins RA, White G, Bundred NJ, et al. Prognostic significance of oestrogen and progesterone receptor activities in breast cancer. Br J Surg 1987; 74: 1009-13.
11. Sutton R, Campbell M, Cooke T, Nicholson R, Griffiths K, Taylor I. Predictive power of progesterone receptor in early breast carcinoma. Br J Surg 1987; 74: 223-6.
12. Luqmani YA, Ricketts D, Ryall G, Turnbull L, Law M, Coombes RC. Prediction of response to endocrine therapy in breast cancer using immunohistochemical assays for pS2, estrogen receptor and progesterone receptor. Int J Cancer 1993; 54: 619-23.
13. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acid Res 1982; 10: 7895-901.
14. Nunez AM, Berry M, Imler J, Chambon P. The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J 1989; 8: 823-9.
15. Luqmani YA, Ryall G, Shousha S, Coombes RC. An immunohistochemical survey of pS2 expression in epithelial cancers. Int J Cancer 1992; 50: 302-4.
16. Thim L. A new family of growth factor like peptides. Febs Lett 1989; 250: 85-90.
17. Lefebvre O, Chenard MP, Masson R. Gastric mucosa abnormalities and tumourigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-62.
18. Luqmani YA, Campbell T, Soomro S, Shousha S, Rio MC, Coombes RC. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Br J Cancer 1993; 67: 749-53.
19. Williams R, Stamp GWH, Gilbert C, Pignatelli M, Lalani EN. pS2 transfection of murineadenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3D collagen gel. J Cell Sci 1996; 109: 63-71.
20. Rio MC, Bellocq JP, Gairard B. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene erbB2. Proc Natl Acad Sci USA 1987; 84: 9243-7.
21. Skilton RA, Luqmani YA, McClelland RA, Coombes RC. Characterisation of a messenger RNA selectively expressed in human breast cancer. Br J Cancer 1989; 60: 168-75.
22. Henry JA, Nicholson S, Hennessy C, Lennard TWJ, May FEB, Westley BR. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer 1989; 61: 32-8.
23. Foekons IA, Rio MC, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990; 50: 3832-7.
24. Foekens IA, Portengen H, Look MP, et al. Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 1994; 70: 1217-23.
25. Goussard I, Lechevrel C, Roussel G, Cren H, Bera O, Sala M. Immunoradiometric assay of pS2 protein in breast cancer cytosols. Clin Chim Acta 1991; 37: 1759-62.
26. Schwartz L, Koerner F, Edgerton SM, et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991; 51: 624-8.
27. Predine J, Spyratos F, Prud'homme JF, et al. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer 1992; 69: 2117-23.
28. Koerner FC, Goldberg DE, Edgerton SM, Schwartz LH. pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer 1992; 52: 183-8.
29. Cappelletti V, Coradini D, Scanziani E, Benini R, Silvestrini R, Di Fronz G. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node negative breast cancer. Eur J Cancer 1992; 28A: 1315-8.
30. Correale M, Paradiso A, Abbate I, et al. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. Tumor Biol 1993; 14: 30-7.
31. Thompson AM, Hawkins RA, Elton RA, Steel CM, Chetty U, Carter DC. pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 1993; 68: 93-6.
32. Gion M, Mione R, Pappagallo GL, et al. pS2 in breast cancer alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 1993; 68: 371-9.
33. Detre S, King N, Salter J, Maclennan K, Mckinna JA, Dowsett M. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. J Clin Pathol 1994; 47: 240-4.
34. Speiser P, Stolzlechner J, Haider K, et al. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res 1994; 14: 2125-30.
35. Wysocki S, Hahnel E, Wilkinson SP, Smith V, Hahnel R. Hormono-sensitive gene expression in breast tumours. Anti-cancer Res 1990; 10: 185-8.
36. Spyratos F, Andrieu C, Hacene K, Chambon P, Rio MC. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994; 69: 394-7.
37. Soubeyran I, Wafflart J, Bonichon F, et al. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995; 34: 119-28.
38. Walker RA, Rajakariar R, Dookeran KA. Comparison of pS2 and cathepsin D in primary breast cancer. The Breast 1995; 4: 137-42.
39. Horiguchi J, Lino Y, Takei H. Expression of pS2 estrogen-inducible protein in primary breast cancer. Oncology 1996; 53: 12-5.
40. Henry IA, Piggott NH, Mallick UK, et al. pNR2 pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 1991; 63: 615-22.
41. Dookeran KA, Rye PD, Dearing SJ, Walker RA. Expression of the pS2 peptide in primary breast carcinomas: comparison of membrane and cytoplasmic staining patterns. J Pathol 1993; 171: 123-9.
42. Takahashi S, Narimatsu E, Asanuma H, et al. Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products. Oncology 1995; 52: 371-5.
43. Luqmani YA, Temmim L, Memon A, Ali MAA, Parkar AH. Steroid receptor measurements in breast cancers: comparison between ligand binding and enzyme immunoassay in cytosolic and nuclear extracts. Int J Cancer 1997; 71: 526-38.
44. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248-54.
45. Grebenschikov N, Geurts-Moespot A, Dewitte H, et al. A sensitive and robust assay for urokinase and tissue type plasminogen activators (Upa and tPA) and their inhibitor type 1 (PA1-1) in breast cancer cytosols. Int J Biol Markers 1997; 12: 6-14.
46. Correale M, Abbate A, Paradiso A, et al. pS2-a new cytosolic protein recognised by monoclonal antibodies as a marker of hormone sensitivity in breast cancer. Cell Biophys 1993a; 22: 101-10.
47. Pichon MF, Milgrom E. Clinical significance of the estrogen regulated pS2 protein in mammary tumors. Clin Rev Oncol Haematol 1993; 15: 13-21.
48. Barrett-Lee PJ, Travers M, McClelland RA, Luqmani YA, Coombes RC. Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res 1987; 47: 6653-9.
49. Romain S, Laine-Bidron C, Martin PM, Magdelenat H. on behalf of the EORTC receptor study group. Steroid receptor distribution in 47892 breast cancers. A collaborative study of 7 European laboratories. Eur J Cancer 1995; 31A: 411-7.
50. Foekens JA, Schmitt M, Van Putten WLJ, et al. Prognostic value of urokinase type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-5.
51. Janicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78.
52. Janicke F, Pache L, Schmitt M, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase type plasminogen activator and its inhibitor plasmonogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-30.
53. Yamashita J, Ogawa M, Yamashita S, et al. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 1993; 68: 524-9.